The role of intranasal oxytocin in the treatment of patients with schizophrenia: A systematic review

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 2, 2013, Pages 252-264

  de Berardis, Domenico ^a,b   Marini, Stefano ^a,b   Iasevoli, Felice ^c   Tomasetti, Carmine ^c   de Bartolomeis, Andrea ^c   Mazza, Monica ^d   Valchera, Alessandro ^e   Fornaro, Michele ^f,g   Cavuto, Marilde ^h   Srinivasan, Venkataramanujam ⁱ   Sepede, Gianna ^b   Martinotti, Giovanni ^b   Di Giannantonio, Massimo ^b  

^a G Mazzini Hospital   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e Hermanas Hospitalarias   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h IASM   (Italy)

ⁱ Sri Sathya Sai Medical Educational and Research Foundation   (India)

Author keywords

Emotions; Intranasal oxytocin; Review; Schizophrenia; Social cognition

Indexed keywords

OXYTOCIN; PLACEBO;

COGNITION; DISEASE CLASSIFICATION; DRUG EFFICACY; EMOTION; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOGNITION; REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; SYSTEMATIC REVIEW;

ADMINISTRATION, INTRANASAL; ANIMALS; COGNITION DISORDERS; HUMANS; INTERPERSONAL RELATIONS; OXYTOCIN; SCHIZOPHRENIA;

EID: 84876708248     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527311312020012     Document Type: Review

References (145)

1. Brownstein, M.J.; Russell, J.T.; Gainer, H. Synthesis, transport, and release of posterior pituitary hormones. Science, 1980, 207, 373-378.
2. Young, W.S., 3rd; Gainer, H. Transgenesis and the study of expression, cellular targeting and function of oxytocin, vasopressin and their receptors. Neuroendocrinology, 2003, 78, 185-203.
3. Bosch, O.J.; Meddle, S.L.; Beiderbeck, D.I.; Douglas, A.J.; Neumann, I.D. Brain oxytocin correlates with maternal aggression: link to anxiety. J. Neurosci., 2005, 25, 6807-6815.
4. Insel, T.R.; Gelhard, R.; Shapiro, L.E. The comparative distribution of forebrain receptors for neurohypophyseal peptides in monogamous and polygamous mice. Neuroscience, 1991, 43, 623-630.
5. Bartz, J.A.; Zaki, J.; Bolger, N.; Ochsner, K.N. Social effects of oxytocin in humans: context and person matter. Trends Cogn. Sci., 2011, 15, 301-309.
6. Veinante, P.; Freund-Mercier, M.J. Distribution of oxytocin-and vasopressin-binding sites in the rat extended amygdala: a histoautoradiographic study. J. Comp. Neurol., 1997, 383, 305-325.
7. Landgraf, R.; Neumann, I.D. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front. Neuroendocrinol., 2004, 25, 150-176.
8. Heinrichs, M.; Domes, G. Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans. Prog. Brain Res., 2008, 170, 337-350.
9. Carter, C.S. Sex differences in oxytocin and vasopressin: implications for autism spectrum disorders? Behav. Brain Res., 2007, 176, 170-186.
10. Uhl-Bronner, S.; Waltisperger, E.; Martinez-Lorenzana, G.; Condes Lara, M.; Freund-Mercier, M.J. Sexually dimorphic expression of oxytocin binding sites in forebrain and spinal cord of the rat. Neuroscience, 2005, 135, 147-154.
11. Francis, D.D.; Young, L.J.; Meaney, M.J.; Insel, T.R. Naturally occurring differences in maternal care are associated with the expression of oxytocin and vasopressin (V1a) receptors: gender differences. J. Neuroendocrinol., 2002, 14, 349-353.
12. Lambert, R.C.; Dayanithi, G.; Moos, F.C.; Richard, P. A rise in the intracellular Ca2+ concentration of isolated rat supraoptic cells in response to oxytocin. J. Physiol., 1994, 478(2), 275-287.
13. Dayanithi, G.; Sabatier, N.; Widmer, H. Intracellular calcium signalling in magnocellular neurones of the rat supraoptic nucleus: understanding the autoregulatory mechanisms. Exp. Physiol., 2000, 85(Spec No), 75S-84S.
14. Forsling, M.L.; Kallo, I.; Hartley, D.E.; Heinze, L.; Ladek, R.; Coen, C.W.; File, S.E. Oestrogen receptor-beta and neurohypophysial hormones: functional interaction and neuroanatomical localisation. Pharmacol. Biochem. Behav., 2003, 76, 535-542.
15. Larcher, A.; Neculcea, J.; Breton, C.; Arslan, A.; Rozen, F.; Russo, C.; Zingg, H.H. Oxytocin receptor gene expression in the rat uterus during pregnancy and the estrous cycle and in response to gonadal steroid treatment. Endocrinology, 1995, 136, 5350-5356.
16. Tribollet, E.; Barberis, C.; Arsenijevic, Y. Distribution of vasopressin and oxytocin receptors in the rat spinal cord: sexrelated differences and effect of castration in pudendal motor nuclei. Neuroscience, 1997, 78, 499-509.
17. Sakamoto, H.; Matsuda, K.; Hosokawa, K.; Nishi, M.; Morris, J.F.; Prossnitz, E.R.; Kawata, M. Expression of G protein-coupled receptor-30, a G protein-coupled membrane estrogen receptor, in oxytocin neurons of the rat paraventricular and supraoptic nuclei. Endocrinology, 2007, 148, 5842-5850.
18. Widmer, H.; Ludwig, M.; Bancel, F.; Leng, G.; Dayanithi, G. Neurosteroid regulation of oxytocin and vasopressin release from the rat supraoptic nucleus. J. Physiol., 2003, 548, 233-244.
19. Theodosis, D.T.; Poulain, D.A. Activity-dependent neuronal-glial and synaptic plasticity in the adult mammalian hypothalamus. Neuroscience, 1993, 57, 501-535.
20. Deng, W.; Aimone, J.B.; Gage, F.H. New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nat. Rev. Neurosci., 2010, 11, 339-350.
21. Griffin, G.D.; Ferri-Kolwicz, S.L.; Reyes, B.A.; Van Bockstaele, E.J.; Flanagan-Cato, L.M. Ovarian hormone-induced reorganization of oxytocin-labeled dendrites and synapses lateral to the hypothalamic ventromedial nucleus in female rats. J. Comp. Neurol., 2010, 518, 4531-4545.
22. Argiolas, A.; Melis, M.R. Central control of penile erection: role of the paraventricular nucleus of the hypothalamus. Prog. Neurobiol., 2005, 76, 1-21.
23. Smeltzer, M.D.; Curtis, J.T.; Aragona, B.J.; Wang, Z. Dopamine, oxytocin, and vasopressin receptor binding in the medial prefrontal cortex of monogamous and promiscuous voles. Neurosci. Lett., 2006, 394, 146-151.
24. van Vulpen, E.H.; Yang, C.R.; Nissen, R.; Renaud, L.P. Hypothalamic A14 and A15 catecholamine cells provide the dopaminergic innervation to the supraoptic nucleus in rat: a combined retrograde tracer and immunohistochemical study. Neuroscience, 1999, 93, 675-680.
25. Baskerville, T.A.; Douglas, A.J. Interactions between dopamine and oxytocin in the control of sexual behaviour. Prog. Brain Res., 2008, 170, 277-290.
26. Young, K.A.; Gobrogge, K.L.; Liu, Y.; Wang, Z. The neurobiology of pair bonding: insights from a socially monogamous rodent. Front. Neuroendocrinol., 2011, 32, 53-69.
27. Numan, M.; Insel, T.R. The Neurobiology of Parental Behavior. New York: Springer. 2003.
28. Liu, Y.; Wang, Z.X. Nucleus accumbens oxytocin and dopamine interact to regulate pair bond formation in female prairie voles. Neuroscience, 2003, 121, 537-544.
29. Sanchez-Andrade, G.; Kendrick, K.M. The main olfactory system and social learning in mammals. Behav. Brain Res., 2009, 200, 323-335.
30. Insel, T.R.; Young, L.J. The neurobiology of attachment. Nat. Rev. Neurosci., 2001, 2, 129-136.
31. Shahrokh, D.K.; Zhang, T.Y.; Diorio, J.; Gratton, A.; Meaney, M.J. Oxytocin-dopamine interactions mediate variations in maternal behavior in the rat. Endocrinology, 2010, 151, 2276-2286.
32. Kovacs, G.L.; Sarnyai, Z.; Barbarczi, E.; Szabo, G.; Telegdy, G. The role of oxytocin-dopamine interactions in cocaine-induced locomotor hyperactivity. Neuropharmacology, 1990, 29, 365-368.
33. Sarnyai, Z.; Babarczy, E.; Krivan, M.; Szabo, G.; Kovacs, G.L.; Barth, T.; Telegdy, G. Selective attenuation of cocaine-induced stereotyped behaviour by oxytocin: putative role of basal forebrain target sites. Neuropeptides, 1991, 19, 51-56.
34. Qi, J.; Yang, J.Y.; Song, M.; Li, Y.; Wang, F.; Wu, C.F. Inhibition by oxytocin of methamphetamine-induced hyperactivity related to dopamine turnover in the mesolimbic region in mice. Naunyn. Schmiedebergs. Arch. Pharmacol., 2008, 376, 441-448.
35. Carson, D.S.; Cornish, J.L.; Guastella, A.J.; Hunt, G.E.; McGregor, I.S. Oxytocin decreases methamphetamine self-administration, methamphetamine hyperactivity, and relapse to methamphetamineseeking behaviour in rats. Neuropharmacology, 2010, 58, 38-43.
36. Qi, J.; Yang, J.Y.; Wang, F.; Zhao, Y.N.; Song, M.; Wu, C.F. Effects of oxytocin on methamphetamine-induced conditioned place preference and the possible role of glutamatergic neurotransmission in the medial prefrontal cortex of mice in reinstatement. Neuropharmacology, 2009, 56, 856-865.
37. Bujanow, W. Hormones in the treatment of psychoses. Br. Med. J., 1972, 4(5835), 298.
38. Beckmann, H.; Lang, R.E.; Gattaz, W.F. Vasopressin-oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. Psychoneuroendocrinology, 1985, 10, 187-191.
39. Glovinsky, D.; Kalogeras, K.T.; Kirch, D.G.; Suddath, R.; Wyatt, R.J. Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication. Schizophr. Res., 1994, 11, 273-276.
40. Goldman, M.; Marlow-O'Connor, M.; Torres, I.; Carter, C.S. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr. Res., 2008, 98, 247-255.
41. Souza, R.P.; Ismail, P.; Meltzer, H.Y.; Kennedy, J.L. Variants in the oxytocin gene and risk for schizophrenia. Schizophr. Res., 2010, 121, 279-280.
42. Teltsh, O.; Kanyas-Sarner, K.; Rigbi, A.; Greenbaum, L.; Lerer, B.; Kohn, Y. Oxytocin and vasopressin genes are significantly associated with schizophrenia in a large Arab-Israeli pedigree. Int. J. Neuropsychopharmacol., 2011, 7, 1-11.
43. Lim, M.M.; Bielsky, I.F.; Young, L.J. Neuropeptides and the social brain: potential rodent models of autism. Int. J. Dev. Neurosci., 2005, 23, 235-243.
44. Modahl, C.; Green, L.; Fein, D.; Morris, M.; Waterhouse, L.; Feinstein, C.; Levin, H. Plasma oxytocin levels in autistic children. Biol. Psychiatry, 1998, 43, 270-277.
45. Winslow, J.T.; Noble, P.L.; Lyons, C.K.; Sterk, S.M.; Insel, T.R. Rearing effects on cerebrospinal fluid oxytocin concentration and social buffering in rhesus monkeys. Neuropsychopharmacology, 2003, 28, 910-918.
46. Rosenblum, L.A.; Smith, E.L.; Altemus, M.; Scharf, B.A.; Owens, M.J.; Nemeroff, C.B.; Gorman, J.M.; Coplan, J.D. Differing concentrations of corticotropin-releasing factor and oxytocin in the cerebrospinal fluid of bonnet and pigtail macaques. Psychoneuroendocrinology, 2002, 27, 651-660.
47. Gabreels, B.A.; Swaab, D.F.; de Kleijn, D.P.; Seidah, N.G.; Van de Loo, J.W.; Van de Ven, W.J.; Martens, G.J.; van Leeuwen, F.W. Attenuation of the polypeptide 7B2, prohormone convertase PC2, and vasopressin in the hypothalamus of some Prader-Willi patients: indications for a processing defect. J. Clin. Endocrinol. Metab., 1998, 83, 591-599.
48. Green, L.; Fein, D.; Modahl, C.; Feinstein, C.; Waterhouse, L.; Morris, M. Oxytocin and autistic disorder: alterations in peptide forms. Biol. Psychiatry, 2001, 50, 609-613.
49. Lerer, E.; Levi, S.; Salomon, S.; Darvasi, A.; Yirmiya, N.; Ebstein, R.P. Association between the oxytocin receptor (OXTR) gene and autism: relationship to Vineland Adaptive Behavior Scales and cognition. Mol. Psychiatry, 2008, 13, 980-988.
50. Yrigollen, C.M.; Han, S.S.; Kochetkova, A.; Babitz, T.; Chang, J.T.; Volkmar, F.R.; Leckman, J.F.; Grigorenko, E.L. Genes controlling affiliative behavior as candidate genes for autism. Biol. Psychiatry, 2008, 63, 911-916.
51. Jacob, S.; Brune, C.W.; Carter, C.S.; Leventhal, B.L.; Lord, C.; Cook, E.H., Jr. Association of the oxytocin receptor gene (OXTR) in Caucasian children and adolescents with autism. Neurosci. Lett., 2007, 417, 6-9.
52. Wu, S.; Jia, M.; Ruan, Y.; Liu, J.; Guo, Y.; Shuang, M.; Gong, X.; Zhang, Y.; Yang, X.; Zhang, D. Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han population. Biol. Psychiatry, 2005, 58, 74-77.
53. Jin, D.; Liu, H.X.; Hirai, H.; Torashima, T.; Nagai, T.; Lopatina, O.; Shnayder, N.A.; Yamada, K.; Noda, M.; Seike, T.; Fujita, K.; Takasawa, S.; Yokoyama, S.; Koizumi, K.; Shiraishi, Y.; Tanaka, S.; Hashii, M.; Yoshihara, T.; Higashida, K.; Islam, M.S.; Yamada, N.; Hayashi, K.; Noguchi, N.; Kato, I.; Okamoto, H.; Matsushima, A.; Salmina, A.; Munesue, T.; Shimizu, N.; Mochida, S.; Asano, M.; Higashida, H. CD38 is critical for social behaviour by regulating oxytocin secretion. Nature, 2007, 446, 41-45.
54. Munesue, T.; Yokoyama, S.; Nakamura, K.; Anitha, A.; Yamada, K.; Hayashi, K.; Asaka, T.; Liu, H.X.; Jin, D.; Koizumi, K.; Islam, M.S.; Huang, J.J.; Ma, W.J.; Kim, U.H.; Kim, S.J.; Park, K.; Kim, D.; Kikuchi, M.; Ono, Y.; Nakatani, H.; Suda, S.; Miyachi, T.; Hirai, H.; Salmina, A.; Pichugina, Y.A.; Soumarokov, A.A.; Takei, N.; Mori, N.; Tsujii, M.; Sugiyama, T.; Yagi, K.; Yamagishi, M.; Sasaki, T.; Yamasue, H.; Kato, N.; Hashimoto, R.; Taniike, M.; Hayashi, Y.; Hamada, J.; Suzuki, S.; Ooi, A.; Noda, M.; Kamiyama, Y.; Kido, M.A.; Lopatina, O.; Hashii, M.; Amina, S.; Malavasi, F.; Huang, E.J.; Zhang, J.; Shimizu, N.; Yoshikawa, T.; Matsushima, A.; Minabe, Y.; Higashida, H. Two genetic variants of CD38 in subjects with autism spectrum disorder and controls. Neurosci. Res., 2010, 67, 181-191.
55. Lerer, E.; Levi, S.; Israel, S.; Yaari, M.; Nemanov, L.; Mankuta, D.; Nurit, Y.; Ebstein, R.P. Low CD38 expression in lymphoblastoid cells and haplotypes are both associated with autism in a family-based study. Autism Res., 2010, 3, 293-302.
56. Feifel, D.; Reza, T. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacol. Berl., 1999, 141(1), 93-98.
57. De Bartolomeis, A.; Fiore, G.; Iasevoli, F. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. Curr. Pharm. Des., 2005, 11, 3561-3594.
58. Braff, D.L.; Geyer, M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry, 1990, 47, 181-188.
59. Feifel, D.; Shilling, P.D.; Belcher, A.M. The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating. Eur. Neuropsychopharmacol., 2012, 22, 374-378.
60. Javitt, D.C.; Zukin, S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry, 1991, 148, 1301-1308.
61. Qiao, H.; Noda, Y.; Kamei, H.; Nagai, T.; Furukawa, H.; Miura, H.; Kayukawa, Y.; Ohta, T.; Nabeshima, T. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport, 2001, 12, 11-15.
62. Caldwell, H.K.; Stephens, S.L.; Young, W.S. 3rd. Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice. Mol. Psychiatry, 2009, 14, 190-196.
63. Lee, P.R.; Brady, D.L.; Shapiro, R.A.; Dorsa, D.M.; Koenig, J.I. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology, 2005, 30, 1883-1894.
64. Liu, W.; Pappas, G.D.; Carter, C.S. Oxytocin receptors in brain cortical regions are reduced in haploinsufficient (+/-) reeler mice. Neurol. Res., 2005, 27, 339-345.
65. Insel, T.R.; O'Brien, D.J.; Leckman, J.F. Oxytocin, vasopressin, and autism: is there a connection? Biol. Psychiatry, 1999, 45, 145-157.
66. Insel, T.R.; Winslow, J.T.; Wang, Z.X.; Young, L.; Hulihan, T.J. Oxytocin and the molecular basis of monogamy. Adv. Exp. Med. Biol., 1995, 395, 227-234.
67. Bartz, J.A.; McInnes, L.A. CD38 regulates oxytocin secretion and complex social behavior. Bioessays, 2007, 29, 837-841.
68. Lee, H.J.; Macbeth, A.H.; Pagani, J.H.; Young, W.S., 3rd. Oxytocin: the great facilitator of life. Prog. Neurobiol., 2009, 88, 127-151.
69. Engelmann, M.; Ebner, K.; Wotjak, C.T.; Landgraf, R. Endogenous oxytocin is involved in short-term olfactory memory in female rats. Behav. Brain Res., 1998, 90, 89-94.
70. Ferguson, J.N.; Young, L.J.; Hearn, E.F.; Matzuk, M.M.; Insel, T.R.; Winslow, J.T. Social amnesia in mice lacking the oxytocin gene. Nat. Genet., 2000, 25, 284-288.
71. Ferguson, J.N.; Aldag, J.M.; Insel, T.R.; Young, L.J. Oxytocin in the medial amygdala is essential for social recognition in the mouse. J. Neurosci., 2001, 21, 8278-8285.
72. Dluzen, D.E.; Muraoka, S.; Engelmann, M.; Landgraf, R. The effects of infusion of arginine vasopressin, oxytocin, or their antagonists into the olfactory bulb upon social recognition responses in male rats. Peptides, 1998, 19, 999-1005.
73. Popik, P.; van Ree, J.M. Oxytocin but not vasopressin facilitates social recognition following injection into the medial preoptic area of the rat brain. Eur. Neuropsychopharmacol., 1991, 1, 555-560.
74. Choleris, E.; Little, S.R.; Mong, J.A.; Puram, S.V.; Langer, R.; Pfaff, D.W. Microparticle-based delivery of oxytocin receptor antisense DNA in the medial amygdala blocks social recognition in female mice. Proc. Natl. Acad. Sci. USA, 2007, 104, 4670-4675.
75. Choleris, E.; Kavaliers, M.; Pfaff, D.W. Functional genomics of social recognition. J. Neuroendocrinol., 2004, 16, 383-389.
76. Young, L.J.; Wang, Z.; Donaldson, R.; Rissman, E.F. Estrogen receptor alpha is essential for induction of oxytocin receptor by estrogen. Neuroreport, 1998, 9, 933-936.
77. Murakami, G.; Hunter, R.G.; Fontaine, C.; Ribeiro, A.; Pfaff, D. Relationships among estrogen receptor, oxytocin and vasopressin gene expression and social interaction in male mice. Eur. J. Neurosci., 2011, 34, 469-477.
78. Rubin, L.H.; Carter, C.S.; Drogos, L.; Pournajafi-Nazarloo, H.; Sweeney, J.A.; Maki, P.M. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr. Res., 2010, 124, 13-21.
79. Crawley, J.N.; Chen, T.; Puri, A.; Washburn, R.; Sullivan, T.L.; Hill, J.M.; Young, N.B.; Nadler, J.J.; Moy, S.S.; Young, L.J.; Caldwell, H.K.; Young, W.S. Social approach behaviors in oxytocin knockout mice: comparison of two independent lines tested in different laboratory environments. Neuropeptides, 2007, 41, 145-163.
80. Savaskan, E.; Ehrhardt, R.; Schulz, A.; Walter, M., Schachinger, H. Post-learning intranasal oxytocin modulates human memory for facial identity. Psychoneuroendocrinology, 2008, 33, 368-374.
81. Guastella, A.J.; Mitchell, P.B.; Dadds, M.R. Oxytocin increases gaze to the eye region of human faces. Biol. Psychiatry, 2008, 63, 3-5.
82. Rimmele, U.; Hediger, K.; Heinrichs, M.; Klaver, P. Oxytocin makes a face in memory familiar. J. Neurosci., 2009, 29, 38-42.
83. Guastella, A.J.; Carson, D.S.; Dadds, M.R.; Mitchell, P.B.; Cox, R.E. Does oxytocin influence the early detection of angry and happy faces? Psychoneuroendocrinology, 2009, 34, 220-225.
84. Kirsch, P.; Esslinger, C.; Chen, Q.; Mier, D.; Lis, S.; Siddhanti, S.; Gruppe, H.; Mattay, V.S.; Gallhofer, B.; Meyer-Lindenberg, A. Oxytocin modulates neural circuitry for social cognition and fear in humans. J. Neurosci., 2005, 25, 11489-11493.
85. Ross, H.E.; Young, L.J. Oxytocin and the neural mechanisms regulating social cognition and affiliative behavior. Front. Neuroendocrinol., 2009, 30, 534-547.
86. Kosfeld, M.; Heinrichs, M.; Zak, P.J.; Fischbacher, U.; Fehr, E. Oxytocin increases trust in humans. Nature, 2005, 435, 673-676.
87. Keri, S.; Kiss, I.; Kelemen, O. Sharing secrets: oxytocin and trust in schizophrenia. Soc. Neurosci., 2009, 4, 287-293.
88. Macdonald, E.M.; Jackson, H.J.; Hayes, R.L.; Baglioni, A.J.Jr.; Madden, C. Social skill as determinant of social networks and perceived social support in schizophrenia. Schizophr. Res., 1998, 29, 275-286.
89. Heinrichs, M.; Baumgartner, T.; Kirschbaum, C.; Ehlert, U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol. Psychiatry, 2003, 54, 1389-1398.
90. Ditzen, B.; Schaer, M.; Gabriel, B.; Bodenmann, G.; Ehlert, U.; Heinrichs, M. Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict. Biol. Psychiatry, 2009, 65, 728-731.
91. Hill, E.L.; Frith, U. Understanding autism: insights from mind and brain. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 2003, 358, 281-289.
92. Domes, G.; Heinrichs, M.; Michel, A.; Berger, C.; Herpertz, S.C. Oxytocin improves mind-reading in humans. Biol. Psychiatry, 2007, 61, 731-733.
93. Meyer-Lindenberg, A.; Domes, G.; Kirsch, P.; Heinrichs, M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nat. Rev. Neurosci., 2011, 12, 524-538.
94. Tost, H.; Kolachana, B.; Hakimi, S.; Lemaitre, H.; Verchinski, B.A.; Mattay, V.S.; Weinberger, D.R.; Meyer-Lindenberg, A. A common allele in the oxytocin receptor gene (OXTR) impacts prosocial temperament and human hypothalamic-limbic structure and function. Proc. Natl. Acad. Sci. USA, 2010, 107, 13936-13941.
95. Inoue, H.; Yamasue, H.; Tochigi, M.; Abe, O.; Liu, X.; Kawamura, Y.; Takei, K.; Suga, M.; Yamada, H.; Rogers, M.A.; Aoki, S.; Sasaki, T.; Kasai, K. Association between the oxytocin receptor gene and amygdalar volume in healthy adults. Biol. Psychiatry, 2010, 68, 1066-1072.
96. Wermter, A.K.; Kamp-Becker, I.; Hesse, P.; Schulte-Korne, G.; Strauch, K.; Remschmidt, H. Evidence for the involvement of genetic variation in the oxytocin receptor gene (OXTR) in the etiology of autistic disorders on high-functioning level. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2010, 153B(2), 629-639.
97. Goossens, L.; Kukolja, J.; Onur, O.A.; Fink, G.R.; Maier, W.; Griez, E.; Schruers, K.; Hurlemann, R. Selective processing of social stimuli in the superficial amygdala. Hum. Brain Mapp., 2009, 30, 3332-3338.
98. Dalton, K.M.; Nacewicz, B.M.; Johnstone, T.; Schaefer, H.S.; Gernsbacher, M.A.; Goldsmith, H.H.; Alexander, A.L.; Davidson, R.J. Gaze fixation and the neural circuitry of face processing in autism. Nat. Neurosci., 2005, 8, 519-526.
99. Addington, J.; Addington D. Neurocognitive and social functioning in schizophrenia. Schizophr. Bull., 1999, 25(1), 173-182.
100. Pinkham, A.E.; Hopfinger, J.B.; Pelphrey, K.A.; Piven, J.; Penn, D.L. Neural bases for impaired social cognition in schizophrenia and autism spectrum disorders. Schizophr. Res., 2008, 99(1-3), 164-175.
101. Wolf, D.H.; Turetsky, B.I.; Loughead, J.; Elliott, M.A.; Pratiwad, R.; Gur, R.E.; Gur, R.C.; Auditory oddball fmri in schizophrenia: Association of negative symptoms with regional hypoactivation to novel distractors. Brain Imaging Behav., 2008, 2, 132-145.
102. Mazza, M.; Lucci, G.; Pacitti, F.; Pino, M.C.; Mariano, M.; Casacchia, M.; Roncone, R. Could schizophrenic subjects improve their social cognition abilities only with observation andimitation of social situations? Neuropsychol. Rehabil., 2010, 20(5), 675-703.
103. Happe, FG. An advanced test of theory of mind: Understanding of story characters' thoughts andfeelings by able autistic, mentally handicapped, and normal children and adults. J. Autism Dev. Disord., 1994, 24(2), 129-154.
104. Adolphs, R. Social cognition and the human brain. Trends Cogn. Sci., 1999, 3(12), 469-479.
105. Adolphs, R. The neurobiology of social cognition. Curr. Opin. Neurobiol., 2001, 11(2), 231-239.
106. Adolphs, R. How do we know the minds of others? Domainspecificity, simulation, and enactive social cognition. Brain Res., 2006, 1079(1), 25-35.
107. Premack, D.; Woodruff, G. Chimpanzee problem-solving: a test for comprehension. Science, 1978, 23, 532-535.
108. Feifel, D.; Macdonald, K.; Nguyen, A.; Cobb, P.; Warlan, H.; Galangue, B.; Minassian, A.; Becker, O.; Cooper, J.; Perry, W.; Lefebvre, M.; Gonzales, J.; Hadley, A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry, 2010, 68, 678-680.
109. Phelps, E.A.; LeDoux, J.E. Contributions of the amygdala to emotion processing: Fromanimal models to human behavior. Neuron, 2005, 48, 175-187.
110. Bale, T.L.; Davis, A.M.; Auger, A.P.; Dorsa, D.M.; McCarthy, M.M. CNS region-specific oxytocin receptor expression: Importance in regulation of anxiety and sex behavior. J. Neurosci., 2001, 21, 2546-2552.
111. Ferguson, J.N.; Young, L.J.; Insel, T.R. The neuroendocrine basis of social recognition. Front. Neuroendocrinol., 2002, 23, 200-224.
112. Davis, M.; Whalen, P.J. The amygdala: Vigilance and emotion. Mol. Psychiatry, 2001, 6, 13-34.
113. Adolphs, R. Recognizing emotion from facial expressions: Psychological and neurological mechanisms. Behav. Cogn. Neurosci. Rev., 2002, 1, 21-61.
114. Glascher, J.; Tuscher, O.; Weiller, C.; Buchel, C. Elevated responses to constant facial emotionsin different faces in the human amygdala: An fMRI study of facial identity and expression. BMC Neurosci., 2004, 5, 45.
115. Morris, J.S.; Friston, K.J.; Buchel, C.; Frith, C.D.; Young, A.W.; Calder, A.J.; Dolan, R.J. Aneuromodulatory role for the human amygdala in processing emotional facial expressions. Brain, 1998, 121, 47-57.
116. Whalen, P.J.; Rauch, S.L.; Etcoff, N.L.; McInerney, S.C.; Lee, M.B.; Jenike, M.A. Masked presentations of emotional facial expressions modulate amyg-dala activity without explicit knowledge. J. Neurosci., 1998, 18, 411-418.
117. Fitzgerald, D.A.; Angstadt, M.; Jelsone, L.M.; Nathan, P.J.; Phan, K.L. Beyond threat: Amygdala reactivity across multiple expressions of facial affect. Neuroimage, 2006, 30, 1441-1448.
118. Novartis Pharmaceuticals, 2012. Novartis Australia healthcare professionals. Availablefrom: http://www.novartis.com.au/products_healthcare.html (accessed January 01.01.13).
119. Brunton, L.L.; Lazo, J.S.; Parker, K.L. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed. McGraw-Hill Companies, United States, 2006; pp. 1507-1509.
120. Born, J.; Lange, T.; Kern, W.; McGregor, G.P.; Bickel, U.; Fehm, H.L. Sniffing neuropeptides: a transnasal approach to the human brain. Nature, 2012, 5,514-516.
121. Gossen, A.; Hahn, A.; Westphal, L.; Prinz, S.; Schultz, R.T.; Gründer, G.; Spreckelmeyer, K.N. Oxytocin plasma concentrations after single intranasal oxytocin administration-a study in healthy men. Neuropeptides, 2012, 46, 211-215.
122. MacDonald, E.; Dadds, M.R.; Brennan, J.L.; Williams, K.; Levy, F.; Cauchi, A.J. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology, 2011, 36, 1114-1126.
123. Liu J.C.J.; McErlean, R.A.; Dadds, M.R. Are We There Yet? The Clinical Potential of Intranasal Oxytocin in Psychiatry. Curr. Psychiatry Rev., 2012, 8, 37-48.
124. Chapman, C.D.; Frey, W.H.; Craft, S.; Danielyan, L.; Hallschmid, M.; Schiöth, H.B.; Benedict, C. Intranasal treatment of central nervous system dysfunction in humans. Pharm. Res., 2012, in press.
125. Modi, M.E.; Young, L.J. The oxytocin system in drug discovery for autism: animal models and novel therapeutic strategies. Horm. Behav., 2012, 61, 340-350.
126. Guastella, A.J.; Howard, A.L.; Dadds, M.R.; Mitchell, P.; Carson, D.S. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology, 2009, 34, 917-923.
127. Scantamburlo, G.; Ansseau, M.; Geenen, V.; Legros, J.J. Intranasal oxytocin as an adjunct to escitalopram in major depression. J. Neuropsychiatry Clin. Neurosci., 2011, 23, E5.
128. Jesso S, Morlog D, Ross S, Pell MD, Pasternak SH, Mitchell DG, Kertesz A, Finger EC. The effects of oxytocin on social cognition and behaviour in frontotemporal dementia. Brain, 2011, 134(Pt 9):2493-501. doi: 10.1093/brain/awr171.
129. Pedersen, C.A.; Smedley, K.L.; Leserman, J.; Jarskog, L.F.; Rau, S.W.; Kampov-Polevoi, A.; Casey, R.L.; Fender, T.; Garbutt, J.C. Intranasal oxytocin blocks alcohol withdrawal in human subjects. Alcohol Clin. Exp. Res., 2012, in press.
130. den Boer, J.A.; Westenberg, H.G. Oxytocin in obsessive compulsive disorder. Peptides, 1992, 13, 1083-1085.
131. Guastella, A.J.; Einfeld, S.L.; Gray, K.M.; Rinehart, N.J.; Tonge, B.J.; Lambert, T.J.; Hickie, I.B. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol. Psychiatry, 2010, 67, 692-694.
132. Hall, S.S.; Lightbody, A.A.; McCarthy, B.E.; Parker, K.J.; Reiss, A.L. Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology, 2012, 37, 509-518.
133. Anagnostou, E.; Soorya, L.; Chaplin, W.; Bartz, J.; Halpern, D.; Wasserman, S.; Wang, A.T.; Pepa, L.; Tanel, N.; Kushki, A.; Hollander, E. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol. Autism, 2012, 3, 16.
134. Grillon, C.; Krimsky, M.; Charney, D.R.; Vytal, K.; Ernst, M.; Cornwell, B. Oxytocin increases anxiety to unpredictable threat. Mol. Psychiatry, 2012, in press
135. Striepens, N.; Scheele, D.; Kendrick, K.M.; Becker, B.; Schäfer, L.; Schwalba, K.; Reul, J.; Maier, W.; Hurlemann, R. Oxytocin facilitates protective responses to aversive social stimuli in males. Proc. Natl. Acad. Sci. USA, 2012, 109, 18144-181449.
136. Scheele, D.; Striepens, N.; Güntürkün, O.; Deutschländer, S.; Maier, W.; Kendrick, K.M.; Hurlemann, R. Oxytocin modulates social distance between males and females. J. Neurosci., 2012, 32, 16074-16079.
137. Shamay-Tsoory, S.G.; Fischer, M.; Dvash, J.; Harari, H.; Perach-Bloom, N.; Levkovitz, Y. Intranasal administration of oxytocin increases envy and schadenfreude (gloating). Biol. Psychiatry, 2009, 66, 864-870.
138. De Dreu, C.K. Oxytocin modulates cooperation within and competition between groups: an integrative review and research agenda. Horm. Behav., 2012, 61, 419-428.
139. Bartz, J.A.; Zaki, J.; Ochsner, K.N.; Bolger, N.; Kolevzon, A.; Ludwig, N.; Lydon, J.E. Effects of oxytocin on recollections of maternal care and closeness. Proc. Natl. Acad. Sci. USA, 2010, 107, 21371-21375.
140. Bartz, J.A.; Simeon, D.; Hamilton, H.; Kim, S.; Crystal, S.; Braun, A.; Vicens, V.; Hollander, E. Oxytocin can hinder trust and cooperation in borderline personality disorder. Soc. Cogn. Affect. Neurosci., 2011, 6, 556-563.
141. Yamasue, H.; Yee, J.R.; Hurlemann, R.; Rilling, J.K.; Chen, F.S.; Meyer-Lindenberg, A.; Tost, H. Integrative approaches utilizing oxytocin to enhance prosocial behavior: from animal and human social behavior to autistic social dysfunction. J. Neurosci., 2012, 32, 14109-14117.
142. Grillon, C.; Krimsky, M.; Charney, D.R.; Vytal, K.; Ernst, M.; Cornwell, B. Oxytocin increases anxiety to unpredictable threat. Mol. Psychiatry, 2012, in press.
143. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision (DSM-IV-TR). Washington DC, American Psychiatric Press, 2000.
144. Pedersen, C.A.; Gibson, C.M.; Rau, S.W.; Salimi, K.; Smedley, K.L.; Casey, R.L.; Leserman, J. Jarskog, L.F.; Penn, D.L. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr. Res., 2011, 132(1), 50-53.
145. Goldman, M.B.; Gomes, A.M.; Carter, C.S.; Lee, R. Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. Psychopharmacol. Berl., 2011, 216(1), 101-110.